{"id":"NCT04736602","sponsor":"Ipsen","briefTitle":"Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.","officialTitle":"An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-27","primaryCompletion":"2022-02-09","completion":"2022-09-03","firstPosted":"2021-02-03","resultsPosted":"2024-08-01","lastUpdate":"2024-08-01"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Central Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Triptorelin pamoate 15mg","otherNames":[]}],"arms":[{"label":"Triptorelin Pamoate 15mg for injection","type":"EXPERIMENTAL"}],"summary":"The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.","primaryOutcome":{"measure":"Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation","timeFrame":"At Month 3","effectByArm":[{"arm":"All Participants","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":32},"commonTop":["Upper respiratory tract infection","Abnormal weight gain","Bronchitis","Overweight","Vitamin D deficiency"]}}